Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen feels the sales impact from excluding KRAS-positive patients from Vectibix treatment has already occurred, but the firms plans to co-market a test kit shortly.

You may also be interested in...



UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending

The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.

Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?

Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.

Clinical Trial Regs: FDA Seeks Advice On How To Make Them Better, Faster, Stronger

FDA is holding a two-day public hearing to get input on how to modernize its regulation of clinical trials; stakeholders cite need for innovative trial design, data sharing, guidance on use of biomarkers.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS069718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel